Beste apotheek van Nederland

Study
Rosen 2004
AE > 5% in
both treatment
arms
Adverse event
Treatment
Group
% (n/N)
Nausea 24.0 (6/25)
4 mg
36.4 (8/22)
6 mg
Control
Group
% (n/N)
0 (0/24)
Absolute risk
difference (%)
[95% CI]
–
Headache 36.0 (9/25)
4 mg
0 (0/24)
–
27.3 (6/22)
6 mg
Vomiting 8.0 (2/25)
4 mg
0 (0/24) –
9.1 (2/22)
6 mg
Diaphoresis 8 (2/25)
4 mg
0 (0/24) –
Exacerbation of
hypertension
9.1 (2/22)
6 mg
9.1 (2/22)
4 mg
0 (0/24) –
Apomorphine vs. Placebo
Segraves
1991
Eight of 12 patients reported adverse events: yawning, drowsiness and nausea.
Two patients had severe nausea and hypotension
Table 17: Intra-urethral Treatment: Sexual Intercourse
Treatment Control Relative
Study ED Etiology Outcome
Group
% (n/N)
Group
% (n/N)
Risk
[95% CI]
Alprostadil vs. Placebo. Patients randomized included only men who had a maximal penile response
(Grade of 4 or 5 on the Erection Assessment Scale) with at least one dose of alprostadil
Total successful
Padma-
Nathan* 1997
Physiologic:
100%
attempts (diary selfreport)
after 3 months
50.4
(2485/4933)
10.4 (454/4346) 4.82
[4.40–28.00]
Total successful
152